Is everything as bright and sunny as it first appears?

One of the many challenges associated with oncology R&D is picking out the red and green flags associated with early stage trials in order to handicap phase 3 outcomes.

The road to success is paved with many failures along the way.

KRAS has been a hot topic for a while now, yet much of the initial enthusiasm has finally been tempered of late thanks to shorter outcomes than some folks expected with the first generation of targeted therapies – with monotherapy no less!

It’s all too easy to forget KRAS was widely considered ‘undruggable’ or intractable until recently. This doesn’t mean the agents in this space get an easy pass though, far from it.

With new data now out on the first RAS multi agent in the clinic, what’s the story behind the results and what should we be looking for or wary of?

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by